Patients in the trial were those with unresectable hepatocellular carcinoma (HCC) who had not received systemic therapy treatment previously, and were not eligible for localised treatment More: Phase III trial shows AZ’s liver cancer combination improves overall survival Source: News
read moreFierce Pharma Asia—Takeda’s cell, gene therapy deals; BMS-BeiGene Abraxane brawl aliu Fri, 10/15/2021 – 05:47 More: Fierce Pharma Asia—Takeda's cell, gene therapy deals; BMS-BeiGene Abraxane brawl Source: fierce
read moreFDA panel backs half-dose Moderna booster for the elderly and others at high risk kdunleavy Thu, 10/14/2021 – 17:00 More: FDA panel backs half-dose Moderna booster for the elderly and others at high risk Source: fierce
read moreRegeneron pushes its versatile antibody cocktail closer to finish line as a multi-use COVID treatment kdunleavy Thu, 10/14/2021 – 13:57 More: Regeneron pushes its versatile antibody cocktail closer to finish line as a multi-use COVID treatment Source: fierce
read moreA return to the top: Former FDA Commissioner Califf reportedly Biden’s pick for Woodcock’s role klahucik Thu, 10/14/2021 – 13:52 More: A return to the top: Former FDA Commissioner Califf reportedly Biden's pick for Woodcock's role Source: fierce
read moreEntry closes on 22nd October – so don’t miss out on your chance to enter now More: Entry still open for 2021 Marketer of the Year, Sales and Communications Awards! Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals